JP2022511881A5 - - Google Patents

Info

Publication number
JP2022511881A5
JP2022511881A5 JP2021532369A JP2021532369A JP2022511881A5 JP 2022511881 A5 JP2022511881 A5 JP 2022511881A5 JP 2021532369 A JP2021532369 A JP 2021532369A JP 2021532369 A JP2021532369 A JP 2021532369A JP 2022511881 A5 JP2022511881 A5 JP 2022511881A5
Authority
JP
Japan
Prior art keywords
amino acid
hydrophilic
residue
position corresponding
flagellin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021532369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511881A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/064954 external-priority patent/WO2020118192A1/en
Publication of JP2022511881A publication Critical patent/JP2022511881A/ja
Publication of JP2022511881A5 publication Critical patent/JP2022511881A5/ja
Pending legal-status Critical Current

Links

JP2021532369A 2018-12-07 2019-12-06 操作されたフラジェリン由来の組成物と用途 Pending JP2022511881A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776507P 2018-12-07 2018-12-07
US62/776,507 2018-12-07
PCT/US2019/064954 WO2020118192A1 (en) 2018-12-07 2019-12-06 Engineered flagellin-derived compositions and uses

Publications (2)

Publication Number Publication Date
JP2022511881A JP2022511881A (ja) 2022-02-01
JP2022511881A5 true JP2022511881A5 (cg-RX-API-DMAC7.html) 2022-12-14

Family

ID=70974397

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021532369A Pending JP2022511881A (ja) 2018-12-07 2019-12-06 操作されたフラジェリン由来の組成物と用途

Country Status (10)

Country Link
US (1) US20220024991A1 (cg-RX-API-DMAC7.html)
EP (1) EP3890769A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022511881A (cg-RX-API-DMAC7.html)
KR (1) KR20210111770A (cg-RX-API-DMAC7.html)
CN (1) CN113382742A (cg-RX-API-DMAC7.html)
AU (1) AU2019392903A1 (cg-RX-API-DMAC7.html)
CA (1) CA3122067A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191610A1 (cg-RX-API-DMAC7.html)
IL (1) IL283757A (cg-RX-API-DMAC7.html)
WO (1) WO2020118192A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102720967B1 (ko) * 2020-06-04 2024-10-23 가톨릭대학교 산학협력단 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 면역관문억제제의 항암 효과 증진용 약학 조성물
CN119522108A (zh) * 2022-06-01 2025-02-25 弗莱格生物公司 Rna佐剂、其方法和用途
KR102896818B1 (ko) * 2022-10-19 2025-12-08 전남대학교 산학협력단 Tlr5 활성능을 가진 플라젤린 면역증강제 유도체의 진핵세포 발현시스템을 이용한 제조 및 응용
KR20240081501A (ko) * 2022-11-14 2024-06-10 전남대학교산학협력단 암의 치료용 면역증강 살모넬라 균주 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121734B1 (en) * 2007-02-09 2013-05-08 Industry Foundation of Chonam National University Modified flagellin improved toll-like receptor 5 stimulating activity
US9376495B2 (en) * 2011-05-21 2016-06-28 Macrogenics, Inc. Deimmunized serum-binding domains and their use in extending serum half-life
CA2903252C (en) * 2013-03-14 2023-01-17 Research Corporation Technologies, Inc. Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
EP3174893B1 (en) * 2014-07-30 2020-05-06 Genome Protection, Inc. Flagellin compositions and uses

Similar Documents

Publication Publication Date Title
ES2902150T3 (es) Agentes aglutinantes de TIGIT y usos de los mismos
ES2752248T3 (es) Heterodímero proteínico y uso del mismo
JP2020517700A (ja) Stingアゴニストを含む抗体コンジュゲート
IL308807B2 (en) Combination therapy for treating cancer
WO2013036574A4 (en) Modified forms of pseudomonas exotoxin a
AU2013355379A1 (en) Immunotherapy with binding agents
CN104066748A (zh) 抗c-met抗体的纯化
JP7657794B2 (ja) 免疫療法のための組成物及び方法
AU2023294103A1 (en) Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof
WO2017147368A1 (en) Redirecting immune responses
Saini et al. Monoclonal antibodies and antibody-drug conjugates as emerging therapeutics for breast cancer treatment
JP2021512637A5 (cg-RX-API-DMAC7.html)
JP2023536655A5 (cg-RX-API-DMAC7.html)
FI3684813T3 (fi) Agonistisia CD40-vasta-aineita
TW202237190A (zh) 抗cea免疫結合物及其用途
EP3986462A2 (en) Anti-tim-3 antibodies
CN120018857A (zh) Gprc5d tcb与imid的组合疗法
WO2023196876A1 (en) Il-7ralpha-gamma ligand immunoglobulin fusion proteins
CA3075717A1 (en) Combination treatment for cancer
CN111973739A (zh) 抗pd-l1单克隆抗体治疗癌症的用途
IL298883A (en) Transforming growth factor TGF BETA binding agents and their uses
JP2022547809A5 (cg-RX-API-DMAC7.html)
WO2019172358A1 (ja) Hmgn部分ペプチド及びこれを用いたがん療法
ES2900106T3 (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (CHC) y otros tipos de cáncer
EP4090430A1 (en) Method of treating a tumor with a combination of il-7 protein and a bispecific antibody